Evidence map›Paper›PMID 38531949›Full record

ReviewLeukemia2024

Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?

Hagop Kantarjian, Susan Branford, Massimo Breccia, Jorge Cortes, Fadi G Haddad, Andreas Hochhaus, Timothy Hughes, Ghayas C Issa, Elias Jabbour, Franck E Nicolini and 2 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Design, Synthesis, and Biological Evaluation ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 6 countries.

Hagop KantarjianLeukemia Department, MD Anderson Cancer Center, Madrid, Spain. hkantarjian@mdanderson.org.ORCID 0000-0002-1908-3307
Susan BranfordSA Pathology, Centre For Cancer Biology Australia, Adelaide, SA, Australia.
Massimo BrecciaDepartment of Translational and Precision Medicine, Sapienza University-Rome, Rome, Italy.ORCID 0000-0003-1163-6162
Jorge CortesGeorgia Cancer Center, Atlanta, GA, 30303, USA.ORCID 0000-0002-8636-1071
Fadi G HaddadLeukemia Department, MD Anderson Cancer Center, Madrid, Spain.
Andreas HochhausUniversitatsklinikum Jena, Jena, Germany.
Timothy HughesSouth Australian Health & Medical Institute, SAHMRI, Adelaide, SA, Australia.
Ghayas C IssaLeukemia Department, MD Anderson Cancer Center, Madrid, Spain.ORCID 0000-0002-4339-8683
Elias JabbourLeukemia Department, MD Anderson Cancer Center, Madrid, Spain.ORCID 0000-0003-4465-6119
Franck E NicoliniHematology Department and CRCL INSERM U 1052, Centre Léon Berard, Lyon, France.
Koji SasakiLeukemia Department, MD Anderson Cancer Center, Madrid, Spain.ORCID 0000-0002-9140-0610
Francois Xavier-MahonInstitut Bergonié or Bergonié Institute 229 cours de l'Argonne, 33076, Bordeaux, France.
MD Anderson Cancer Center Madrid · ESInserm · FRJena University Hospital · DENational Cancer Center of Georgia · GESapienza University of Rome · ITSouth Australian Health and Medical Research Institute · AUSouth Australia Pathology · AU

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Fusion Proteins, bcr-ablLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTyrosine Kinase InhibitorsHumansProto-Oncogene Proteins c-ablFusion Proteins, bcr-ablProto-Oncogene Proteins c-ablTyrosine Kinase Inhibitors

Identifiers

PMID38531949
PMCPMC12532374
OpenAlexW4393195226

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.